Analysed SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) News Sources
Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the 2025 American Society of Hematology Annual Meeting and Exposition
08-12-2025
yahoo.com
Sumitomo Chemical Co Ltd (SOMMF) (Q1 2027) Earnings Call Highlights: Core Operating Income ...
04-08-2026
yahoo.com
Sumitomo Pharma America Announces First Patient Receives Treatment in Phase 1/2a Study for its Investigational Therapy DSP-3077 for Retinitis Pigmentosa
12-08-2026
yahoo.com
Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight
18-08-2026
yahoo.com
2026 Assessment of the Nuvisertib Market: Sales Forecasts, Clinical Differentiation, Competitive Threats, and Commercial Opportunities Through 2034
10-09-2026
yahoo.com
What is the current price of SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS)?
The current price of SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) is $10.01.
SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) absolute price change since previous trading day?
The absolute price change of SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) since the previous trading day is $0.74.
SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) percentage price change since previous trading day?
The percentage price change of SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) since the previous trading day is 7.9827%.
What is the most recent average sentiment score for SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS)?
The most recent average sentiment score for SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) is 58 out of 100.
What is the most recent average sentiment for SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS)?
The most recent sentiment for SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS) is .
SEC-8K** Filing Available For SUMITOMO PHARMA CO LTD (DNPUF:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.